The National Academy of Medicine announced the election of 90 regular members and 10 international members during its annual meeting Oct. 18-20.
NCI officials were notably absent from the annual meeting of the Association of American Cancer Institutes and the Cancer Center Administrators Forum in Washington, DC, due to the government shutdown that started on Oct. 1.
Scientists, health care professionals, and supporters will take to the streets on Nov. 5, calling for Congress to remove Robert F. Kennedy Jr. from his position as Secretary of Health and Human Services.
Earlier this year, FDA announced that it would be initiating a voucher program aimed at accelerating review time for applications that are deemed to be advancing U.S. “national priorities” (The Cancer Letter, June 20, 2025).
A court filing by Thomas Nagy Jr., deputy assistant secretary for Human Resources and chief human capital officer at HHS, claims that his department can proceed with the 982 RIFs it issued two weeks ago, despite a judge’s temporary order freezing the notices issued by two dozen federal agencies since the government shutdown that began on Oct 1.
With the start of open enrollment less than one week away, millions of Americans are getting their first look at the sharp increases many will pay next year if Congress fails to extend the enhanced premium tax credits that have expanded healthcare access to over 13 million people since 2021.
President Donald Trump has announced a deal with pharmaceutical company Merck KGaA and its U.S. subsidiary, EMD Serono, to sharply reduce the cost of certain fertility drugs used for in-vitro fertilization, or IVF.
Alan KormanAviv RegevJeffrey C. RathmellThe Cancer Research Institute has announced the 2025 recipients of the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology and the Frederick W. Alt Award for New Discoveries in Immunology.
The American College of Radiology has announced the 2026 Gold Medalists and Honorary Fellows Recipients to be recognized during ACR 2026, the college’s annual meeting in Washington, DC, May 2-6, 2026.
Combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer live longer and control their disease better than with the standard treatment drug regorafenib, according to a study led by UCLA investigators.
